$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2012 Q2 Form 10-Q Financial Statement

#000106282212000021 Filed on May 03, 2012

Income Statement

Concept	2012 Q2	2012 Q1	2011 Q1
Revenue	$199.0K	$300.0K	$596.0K
YoY Change	-64.14%	-49.66%	-62.75%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.100M	$5.600M	$5.600M
YoY Change	-5.56%	0.0%	1.82%
% of Gross Profit
Research & Development	$19.36M	$23.04M	$23.92M
YoY Change	-3.92%	-3.7%	13.37%
% of Gross Profit
Depreciation & Amortization	$1.100M	$1.125M	$1.307M
YoY Change	-15.38%	-13.93%	-6.64%
% of Gross Profit
Operating Expenses	$25.68M	$29.68M	$29.73M
YoY Change	-3.03%	-0.16%	11.77%
Operating Profit	-$25.48M	-$29.38M	-$29.14M
YoY Change	-1.72%	0.85%
Interest Expense	$530.0K	$537.0K	$607.0K
YoY Change	-34.57%	-11.53%	-251.75%
% of Operating Profit
Other Income/Expense, Net	$21.00K	-$4.000K	$27.00K
YoY Change	-30.0%	-114.81%	-103.86%
Pretax Income	-$25.90M	-$29.90M	-$29.60M
YoY Change	-2.63%	1.01%	13.41%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$25.93M	-$29.87M	-$29.63M
YoY Change	-2.65%	0.81%	13.52%
Net Earnings / Revenue	-13030.65%	-9956.0%	-4971.31%
Basic Earnings Per Share
Diluted Earnings Per Share	-$377.0K	-$435.9K	-$614.1K
COMMON SHARES
Basic Shares Outstanding	480.7M shares	480.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q2	2012 Q1	2011 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$231.1M	$253.2M	$188.9M
YoY Change	40.57%	34.04%	-39.88%
Cash & Equivalents	$33.78M	$29.01M	$20.12M
Short-Term Investments	$197.3M	$224.2M	$168.8M
Other Short-Term Assets	$6.582M	$5.143M	$3.400M
YoY Change	69.9%	51.26%	-41.38%
Inventory
Prepaid Expenses
Receivables	$182.0K	$186.0K	$800.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$238.3M	$259.0M	$193.2M
YoY Change	40.83%	34.05%	-39.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$44.53M	$45.53M	$51.80M
YoY Change	-7.95%	-12.11%	-10.54%
Goodwill	$44.54M	$44.54M
YoY Change	0.0%
Intangibles	$53.56M	$53.56M
YoY Change	0.0%
Long-Term Investments
YoY Change
Other Assets	$157.0K	$181.0K	$300.0K
YoY Change	-37.94%	-39.67%	-91.89%
Total Long-Term Assets	$142.8M	$143.8M	$150.2M
YoY Change	-2.69%	-4.26%	72.05%
TOTAL ASSETS
Total Short-Term Assets	$238.3M	$259.0M	$193.2M
Total Long-Term Assets	$142.8M	$143.8M	$150.2M
Total Assets	$381.1M	$402.8M	$343.4M
YoY Change	20.62%	17.3%	-16.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.579M	$5.324M	$5.500M
YoY Change	24.73%	-3.2%	14.58%
Accrued Expenses	$15.05M	$13.71M	$7.700M
YoY Change	87.2%	78.05%	42.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.510M	$1.478M	$1.200M
YoY Change	9.42%	23.17%	-96.72%
Total Short-Term Liabilities	$21.56M	$20.93M	$14.50M
YoY Change	62.97%	44.37%	-69.34%
LONG-TERM LIABILITIES
Long-Term Debt	$22.68M	$23.06M	$27.00M
YoY Change	-6.24%	-14.58%	-4.26%
Other Long-Term Liabilities	$59.28M	$57.17M	$63.80M
YoY Change	15.42%	-10.39%	331.08%
Total Long-Term Liabilities	$81.95M	$80.23M	$90.80M
YoY Change	8.48%	-11.64%	111.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.56M	$20.93M	$14.50M
Total Long-Term Liabilities	$81.95M	$80.23M	$90.80M
Total Liabilities	$136.2M	$133.8M	$124.1M
YoY Change	11.86%	7.83%	37.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$845.4M	-$819.5M
YoY Change	15.86%
Common Stock	$481.0K	$481.0K
YoY Change	42.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$630.0K	$630.0K
YoY Change	82.61%
Treasury Stock Shares	380.0K shares	380.0K shares
Shareholders Equity	$244.9M	$269.0M	$219.3M
YoY Change
Total Liabilities & Shareholders Equity	$381.1M	$402.8M	$343.4M
YoY Change	20.62%	17.3%	-16.08%

Cashflow Statement

Concept	2012 Q2	2012 Q1	2011 Q1
OPERATING ACTIVITIES
Net Income	-$25.93M	-$29.87M	-$29.63M
YoY Change	-2.65%	0.81%	13.52%
Depreciation, Depletion And Amortization	$1.100M	$1.125M	$1.307M
YoY Change	-15.38%	-13.93%	-6.64%
Cash From Operating Activities	-$22.00M	-$27.00M	-$21.54M
YoY Change	-7.17%	25.36%	-0.74%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	$234.0K	$507.0K
YoY Change	-66.67%	-53.85%	-201.4%
Acquisitions
YoY Change
Other Investing Activities	$26.90M	-$129.3M	-$4.800M
YoY Change	0.37%	2593.75%	-284.62%
Cash From Investing Activities	$26.90M	-$129.6M	-$5.318M
YoY Change	1.51%	2336.54%	-353.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$233.0K	-$52.00K
YoY Change		-548.08%	-100.03%
Debt Paid & Issued, Net		$353.0K	$284.0K
YoY Change		24.3%
Cash From Financing Activities	-200.0K	-$722.0K	-$232.0K
YoY Change	-92.31%	211.21%	-100.13%
NET CHANGE
Cash From Operating Activities	-22.00M	-$27.00M	-$21.54M
Cash From Investing Activities	26.90M	-$129.6M	-$5.318M
Cash From Financing Activities	-200.0K	-$722.0K	-$232.0K
Net Change In Cash	4.700M	-$157.3M	-$27.09M
YoY Change	2250.0%	480.65%	-116.97%
FREE CASH FLOW
Cash From Operating Activities	-$22.00M	-$27.00M	-$21.54M
Capital Expenditures	-$100.0K	$234.0K	$507.0K
Free Cash Flow	-$21.90M	-$27.24M	-$22.05M
YoY Change	-6.41%	23.54%	4.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6042000	USD
CY2012Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5324000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	350000	USD
CY2012Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	186000	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13786000	USD
CY2012Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13710000	USD
CY2012Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	81654000	USD
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80535000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21000	USD
CY2012Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-57000	USD
CY2012Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1088666000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1087033000	USD
CY2011Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1472000	USD
CY2012Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1718000	USD
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2012Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2012Q1	us-gaap	Assets Assets	402792000	USD
CY2011Q4	us-gaap	Assets Assets	430512000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	285790000	USD
CY2012Q1	us-gaap	Assets Current AssetsCurrent	258985000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	186309000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29010000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47208000	USD
CY2011Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20118000	USD
CY2012Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13910000	USD
CY2012Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	421000	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14212000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-157299000	USD
CY2011Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-27090000	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2012Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2012Q1	us-gaap	Common Stock Value CommonStockValue	481000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	480000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29946000	USD
CY2011Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29594000	USD
CY2012Q1	us-gaap	Contracts Revenue ContractsRevenue	152000	USD
CY2011Q1	us-gaap	Contracts Revenue ContractsRevenue	516000	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	119000	USD
CY2012Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2011Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1307000	USD
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1125000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2011Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2011Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4753000	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4565000	USD
CY2011Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2012Q1	us-gaap	Goodwill Goodwill	44543000	USD
CY2011Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	769000	USD
CY2012Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2011Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3849000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	851000	USD
CY2011Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	87000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-164000	USD
CY2011Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	29000	USD
CY2012Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2011Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	315000	USD
CY2012Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	24000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1395000	USD
CY2011Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-565000	USD
CY2012Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2011Q1	us-gaap	Interest Expense InterestExpense	607000	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	537000	USD
CY2012Q1	us-gaap	Interest Paid Net InterestPaidNet	516000	USD
CY2011Q1	us-gaap	Interest Paid Net InterestPaidNet	584000	USD
CY2011Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	87000	USD
CY2012Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	56000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	132944000	USD
CY2012Q1	us-gaap	Liabilities Liabilities	133821000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	430512000	USD
CY2012Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	402792000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21390000	USD
CY2012Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20933000	USD
CY2011Q1	us-gaap	Licenses Revenue LicensesRevenue	80000	USD
CY2012Q1	us-gaap	Licenses Revenue LicensesRevenue	148000	USD
CY2011Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1443000	USD
CY2012Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1478000	USD
CY2011Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23451000	USD
CY2012Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23063000	USD
CY2011Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-232000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-722000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-129575000	USD
CY2011Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5318000	USD
CY2011Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21540000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27002000	USD
CY2011Q1	us-gaap	Net Income Loss NetIncomeLoss	-29629000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-29868000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	29683000	USD
CY2011Q1	us-gaap	Operating Expenses OperatingExpenses	29732000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-29383000	USD
CY2011Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-29136000	USD
CY2012Q1	us-gaap	Other Assets Current OtherAssetsCurrent	5143000	USD
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3748000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	205000	USD
CY2012Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	181000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-78000	USD
CY2011Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	35000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	55146000	USD
CY2012Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	57170000	USD
CY2011Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	27000	USD
CY2012Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000	USD
CY2011Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	108000	USD
CY2012Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	285000	USD
CY2011Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	33895000	USD
CY2012Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	151776000	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	234000	USD
CY2011Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	507000	USD
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	268971000	USD
CY2010Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	247024000	USD
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	52000	USD
CY2011Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	160000	USD
CY2012Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-136000	USD
CY2011Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2011Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	29041000	USD
CY2012Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	22435000	USD
CY2011Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	43000	USD
CY2012Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2012Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	45526000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46417000	USD
CY2012Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	353000	USD
CY2011Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	284000	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23037000	USD
CY2011Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23921000	USD
CY2011Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2012Q1	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2012Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-819489000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-789621000	USD
CY2011Q1	us-gaap	Revenues Revenues	596000	USD
CY2012Q1	us-gaap	Revenues Revenues	300000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1718000	USD
CY2011Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1472000	USD
CY2012Q1	us-gaap	Short Term Investments ShortTermInvestments	224646000	USD
CY2011Q4	us-gaap	Short Term Investments ShortTermInvestments	95383000	USD
CY2011Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	523000	USD
CY2012Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	52000	USD
CY2012Q1	us-gaap	Stockholders Equity StockholdersEquity	268971000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	297568000	USD
CY2011Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	219317000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	297568000	USD
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	218000	shares
CY2012Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	380000	shares
CY2012Q1	us-gaap	Treasury Stock Value TreasuryStockValue	630000	USD
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	345000	USD
CY2011Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	-108000	USD
CY2012Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	-285000	USD
CY2011Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	35000	USD
CY2012Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-78000	USD
CY2011Q1	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1058000	USD
CY2012Q1	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	2081000	USD
CY2011Q1	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	337527000	shares
CY2012Q1	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	480324000	shares
CY2011Q1	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	633000	USD
CY2012Q1	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	681000	USD
CY2012Q1	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1037000	USD
CY2011Q1	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	839000	USD
CY2012Q1	dei	Amendment Flag AmendmentFlag	false
CY2012Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2012Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012Q1	dei	Document Period End Date DocumentPeriodEndDate	2012-03-31
CY2012Q1	dei	Document Type DocumentType	10-Q
CY2012Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2012Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	480656570	shares
CY2012Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2012Q1	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE

Files In Submission

Name	View Source	Status
0001062822-12-000021-index-headers.html	Edgar Link	pending
0001062822-12-000021-index.html	Edgar Link	pending
0001062822-12-000021.txt	Edgar Link	pending
0001062822-12-000021-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
lxrx-20120331.xml	Edgar Link	completed
lxrx-20120331.xsd	Edgar Link	pending
lxrx-20120331_cal.xml	Edgar Link	unprocessable
lxrx-20120331_def.xml	Edgar Link	unprocessable
lxrx-20120331_lab.xml	Edgar Link	unprocessable
lxrx-20120331_pre.xml	Edgar Link	unprocessable
lxrx331201210-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2012 Q2 Form 10-Q Financial Statement

#000106282212000021 Filed on May 03, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2012 Q2 Form 10-Q Financial Statement

#000106282212000021 Filed on May 03, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx